Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)
Diabetes
About this trial
This is an interventional treatment trial for Diabetes
Eligibility Criteria
Inclusion Criteria:
- Clinically healthy or Clinical diagnosis of Type 2 diabetes on a stable dose of metformin monotherapy
Exclusion Criteria:
- Type 1 Diabetes
- History of significant heart disease
- Prior bariatric surgery
- Women of childbearing potential
Sites / Locations
- Comprehensive Phase One
- Ppd Development, Lp
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Arm 11
Arm 12
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
BMS-903452 (0.1 mg) or Placebo - A1
BMS-903452 (0.6 mg) or Placebo - A2
BMS-903452 (3.0 mg) or Placebo - A3
BMS-903452 (10 mg) or Placebo - A4
BMS-903452 (30 mg) or Placebo - A5
BMS-903452 (60 mg) or Placebo - A6
BMS-903452 (120 mg) or Placebo - A7
BMS-903452 (0.6 mg) or Placebo - B1
BMS-903452 (10 mg) or Placebo - B2
BMS-903452 (120 mg) or Placebo - B3
BMS-903452 (10 mg) or Placebo - A11
BMS-903452 (60 mg) or Placebo - A12
(Healthy Subjects)
(Healthy Subjects)
(Healthy Subjects)
(Healthy Subjects)
(Healthy Subjects)
(Healthy Subjects)
(Healthy Subjects)
(Subjects with type 2 Diabetes Mellitus)
(Subjects with type 2 Diabetes Mellitus)
(Subjects with type 2 Diabetes Mellitus)
(Healthy Subjects)
(Healthy Subjects)